Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, VIC 3168 Australia.
Diabetes and Vascular Medicine Unit, Monash Health, Clayton, VIC 3168, Australia.
Nutrients. 2019 Nov 27;11(12):2888. doi: 10.3390/nu11122888.
In animal studies, vitamin D supplementation has been shown to improve gut microbiota and intestinal inflammation. However, limited evidence exists on the effect of vitamin D supplementation on the human gut microbiota. We examined the effect of vitamin D supplementation on faecal microbiota in 26 vitamin D-deficient (25-hydroxyvitamin D (25(OH)D) ≤50 nmol/L), overweight or obese (BMI ≥25 kg/m) otherwise healthy adults. Our study was ancillary to a community based double-blind randomised clinical trial, conducted between 2014 and 2016. The participants provided stool samples at baseline and after 100,000 international units (IU) loading dose of cholecalciferol followed by 4000 IU daily or matching placebo for 16 weeks. Faecal microbiota was analysed using 16S rRNA sequencing; V6-8 region. There was no significant difference in microbiome α-diversity between vitamin D and placebo groups at baseline and follow-up (all > 0.05). In addition, no clustering was found based on vitamin D supplementation at follow-up ( = 0.3). However, there was a significant association between community composition and vitamin D supplementation at the genus level ( = 0.04). The vitamin D group had a higher abundance of genus , and lower abundance of genus (linear discriminate analysis >3.0). Moreover, individuals with 25(OH)D >75 nmol/L had a higher abundance of genus and lower abundance of genus compared to those with 25(OH)D <50 nmol/L. Our findings suggest that vitamin D supplementation has some distinct effects on faecal microbiota. Future studies need to explore whether these effects would translate into improved clinical outcomes.
在动物研究中，维生素 D 补充已被证明可改善肠道微生物群和肠道炎症。然而，关于维生素 D 补充对人类肠道微生物群的影响，证据有限。我们研究了维生素 D 补充对 26 名维生素 D 缺乏症（25-羟维生素 D（25（OH）D）≤50nmol/L）、超重或肥胖（BMI≥25kg/m）但其他方面健康的成年人粪便微生物群的影响。我们的研究是基于 2014 年至 2016 年期间进行的一项基于社区的双盲随机临床试验的辅助研究。参与者在基线时和服用胆钙化醇 100,000 国际单位（IU）负荷剂量后 16 周内每天服用 4000IU 维生素 D 或匹配安慰剂时提供粪便样本。使用 16S rRNA 测序；V6-8 区分析粪便微生物群；区。在基线和随访时，维生素 D 组和安慰剂组之间的微生物组 α 多样性没有差异（均>0.05）。此外，在随访时未发现基于维生素 D 补充的聚类（=0.3）。然而，在属水平上，社区组成与维生素 D 补充之间存在显著关联（=0.04）。维生素 D 组属 的丰度较高，属 的丰度较低（线性判别分析>3.0）。此外，与 25（OH）D<50nmol/L 的个体相比，25（OH）D>75nmol/L 的个体属 的丰度较高，属 的丰度较低。我们的研究结果表明，维生素 D 补充对粪便微生物群有一些明显的影响。未来的研究需要探索这些影响是否会转化为改善的临床结果。
